Renin inhibitors in chronic heart failure: The aliskiren observation of heart failure treatment study in context

Clinical Cardiology

Volumn 33, Issue 9, 2010, Pages 536-541

  Krum, Henry ^a   Maggioni, Aldo ^b  

^a MONASH UNIVERSITY   (Australia)

^b ANMCO RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CAPTOPRIL; ENALAPRIL; ENALKIREN; EPLERENONE; LOSARTAN; PLACEBO; RAMIPRIL; REMIKIREN; RENIN; VALSARTAN;

DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SYSTOLIC HEART FAILURE; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DISEASE PROGRESSION; FUMARATES; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 77956895723     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20828     Document Type: Review

References (20)

1. Packer M. Pathophysiology of chronic heart failure. Lancet. 1992;340:88-92.
2. Krum H. Role of renin in heart failure and therapeutic potential of direct renin inhibition. J Renin Angiotensin Aldosterone Syst. 2008;9:177-180.
3. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
4. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
5. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
6. McMurray JJ, Ostergren J, Swedberg K, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771. (Pubitemid 37093916)
7. Konstam MA, Neaton JD, Dickstein K, et al; HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840-1848.
8. Latini R, Masson S, Anand I, et al; Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004;25:292-299.
9. Vergaro G, Fontana M, Poletti R, et al. Plasma renin activity is an independent prognostic factor in chronic heart failure. Eur Heart J. 2008;29((suppl):):393. Abstract.
10. Hollenberg NK. Direct renin inhibition and the kidney. Nat Rev Nephrol. 2010;6:49-55.
11. Buczko W, Hermanowicz JM. Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor. Pharmacol Rep. 2008;60:623-631.
12. Westermann D, Riad A, Lettau O, et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52:1068-1075.
13. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005;46:569-576. (Pubitemid 41376839)
14. Connelly KA, Kelly DJ, Kim S, et al. The direct renin inhibitor, aliskiren, improves cardiac function via direct renin inhibition and via renin receptor modulation in a rodent model of diabetic diastolic heart failure. Circulation. 2008;118:S1166. Abstract 6248.
15. McMurray JJ, Pitt B, Latini R, et al; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
16. Seed A, Gardner R, McMurray J, et al. Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail. 2007;9:1120-1127. (Pubitemid 47633316)
17. Solomon SD, Appelbaum E, Manning WJ, et al; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119:530-537.
18. Solomon SD. ASPIRE Study results. Paper presented at: American College of Cardiology 59th Scientific Sessions; March 16, 2010; Atlanta, GA.
19. Adamopoulos C, Ahmed A, Fay R, et al; EPHESUS Investigators. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail. 2009;11:1099-1105.
20. Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure (ATMOSPHERE). Identifier: NCT00853658. http://www. clinicaltrials.gov. Accessed May 20, 2010.